CL2021002165A1 - Nuevos derivados de compuestos heterociclicos y uso de los mismos - Google Patents
Nuevos derivados de compuestos heterociclicos y uso de los mismosInfo
- Publication number
- CL2021002165A1 CL2021002165A1 CL2021002165A CL2021002165A CL2021002165A1 CL 2021002165 A1 CL2021002165 A1 CL 2021002165A1 CL 2021002165 A CL2021002165 A CL 2021002165A CL 2021002165 A CL2021002165 A CL 2021002165A CL 2021002165 A1 CL2021002165 A1 CL 2021002165A1
- Authority
- CL
- Chile
- Prior art keywords
- heterocyclic compounds
- new derivatives
- compounds
- zeste
- derivative compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4743—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención se refiere a nuevos compuestos derivados heterotricíclicos y al uso de los mismos, y más particularmente, a nuevos compuestos derivados heterotricíclicos que tienen actividad inhibidora contra EZH1 (potenciador de homólogo de zeste 1) y/o EZH2 (potenciador de homólogo de zeste 2), sales farmacéuticamente aceptables de los mismos, o composiciones farmacéuticas que contienen estos compuestos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190019544A KR20200101219A (ko) | 2019-02-19 | 2019-02-19 | 신규한 헤테로트리시클릭 유도체 화합물 및 이의 용도 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2021002165A1 true CL2021002165A1 (es) | 2022-04-22 |
Family
ID=72144293
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2021002165A CL2021002165A1 (es) | 2019-02-19 | 2021-08-16 | Nuevos derivados de compuestos heterociclicos y uso de los mismos |
Country Status (17)
Country | Link |
---|---|
US (1) | US20220135582A1 (es) |
EP (1) | EP3929199A4 (es) |
JP (1) | JP7358491B2 (es) |
KR (1) | KR20200101219A (es) |
CN (1) | CN113423710B (es) |
AU (1) | AU2020226042B2 (es) |
BR (1) | BR112021016448A2 (es) |
CA (1) | CA3130456C (es) |
CL (1) | CL2021002165A1 (es) |
EA (1) | EA202191991A1 (es) |
IL (1) | IL285604A (es) |
MX (1) | MX2021009854A (es) |
PE (1) | PE20211703A1 (es) |
SG (1) | SG11202108940RA (es) |
TW (1) | TWI829869B (es) |
WO (1) | WO2020171606A1 (es) |
ZA (1) | ZA202105970B (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112262143A (zh) | 2018-05-21 | 2021-01-22 | 星座制药公司 | 甲基修饰酶的调节剂、其组合物和用途 |
AU2021203261B1 (en) * | 2020-08-13 | 2021-09-23 | Hanmi Pharmaceutical Co., Ltd. | Novel dioxoloisoquinolinone derivatives and use thereof |
KR102386403B1 (ko) * | 2020-08-13 | 2022-04-15 | 한미약품 주식회사 | 신규한 디옥솔로이소퀴놀린온 유도체 화합물 및 이의 용도 |
WO2022179584A1 (zh) * | 2021-02-26 | 2022-09-01 | 南京药石科技股份有限公司 | 新型ezh2抑制剂及其用途 |
WO2023217018A1 (zh) * | 2022-05-07 | 2023-11-16 | 贝达药业股份有限公司 | Ezh2抑制剂及其在医药上的应用 |
WO2023232025A1 (en) * | 2022-05-31 | 2023-12-07 | Hutchmed Limited | Tricyclic compounds and uses thereof |
WO2023244918A1 (en) | 2022-06-13 | 2023-12-21 | Treeline Biosciences, Inc. | Quinolone bcl6 bifunctional degraders |
WO2023244917A1 (en) | 2022-06-13 | 2023-12-21 | Treeline Biosciences, Inc. | 1,8-naphthyridin-2-one heterobifunctional bcl6 degraders |
WO2024038115A1 (en) | 2022-08-17 | 2024-02-22 | Morphosys Ag | Therapy comprising anti-cd19 antibody and ezh2 modulators |
CN115974856B (zh) * | 2022-12-28 | 2023-08-11 | 北京康立生医药技术开发有限公司 | 一种治疗成人t细胞白血病淋巴瘤药物伐美妥司他的制备方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
WO2013067302A1 (en) * | 2011-11-04 | 2013-05-10 | Glaxosmithkline Intellectual Property (No. 2) Limited | Method of treatment |
UA111305C2 (uk) * | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Конденсовані лактами арилу та гетероарилу |
WO2015077194A1 (en) * | 2013-11-22 | 2015-05-28 | Bristol-Myers Squibb Company | Inhibitors of lysine methyl transferase |
RU2679131C2 (ru) * | 2014-03-17 | 2019-02-06 | Дайити Санкио Компани, Лимитед | Производное 1,3-бензодиоксола |
WO2015193768A1 (en) | 2014-06-17 | 2015-12-23 | Pfizer Inc. | Aryl fused lactams as ezh2 modulators |
GEP20186933B (en) * | 2014-06-17 | 2018-12-10 | Pfizer | Substituted dihydroisoquinoline compounds |
US10308638B2 (en) | 2015-03-25 | 2019-06-04 | The Regents Of The University Of California | Selective alpha-7 nicotinic receptor agonists and methods for making and using them |
CN112262143A (zh) * | 2018-05-21 | 2021-01-22 | 星座制药公司 | 甲基修饰酶的调节剂、其组合物和用途 |
-
2019
- 2019-02-19 KR KR1020190019544A patent/KR20200101219A/ko not_active Application Discontinuation
-
2020
- 2020-02-19 AU AU2020226042A patent/AU2020226042B2/en active Active
- 2020-02-19 EP EP20759257.7A patent/EP3929199A4/en active Pending
- 2020-02-19 CN CN202080013624.0A patent/CN113423710B/zh active Active
- 2020-02-19 MX MX2021009854A patent/MX2021009854A/es unknown
- 2020-02-19 PE PE2021001370A patent/PE20211703A1/es unknown
- 2020-02-19 SG SG11202108940RA patent/SG11202108940RA/en unknown
- 2020-02-19 JP JP2021548205A patent/JP7358491B2/ja active Active
- 2020-02-19 CA CA3130456A patent/CA3130456C/en active Active
- 2020-02-19 TW TW109105374A patent/TWI829869B/zh active
- 2020-02-19 BR BR112021016448A patent/BR112021016448A2/pt unknown
- 2020-02-19 WO PCT/KR2020/002427 patent/WO2020171606A1/ko unknown
- 2020-02-19 EA EA202191991A patent/EA202191991A1/ru unknown
- 2020-02-19 US US17/431,933 patent/US20220135582A1/en active Pending
-
2021
- 2021-08-14 IL IL285604A patent/IL285604A/en unknown
- 2021-08-16 CL CL2021002165A patent/CL2021002165A1/es unknown
- 2021-08-19 ZA ZA2021/05970A patent/ZA202105970B/en unknown
Also Published As
Publication number | Publication date |
---|---|
SG11202108940RA (en) | 2021-09-29 |
CN113423710B (zh) | 2024-06-14 |
MX2021009854A (es) | 2021-09-28 |
TW202045512A (zh) | 2020-12-16 |
IL285604A (en) | 2021-09-30 |
TWI829869B (zh) | 2024-01-21 |
JP2022522648A (ja) | 2022-04-20 |
WO2020171606A1 (ko) | 2020-08-27 |
AU2020226042A1 (en) | 2021-09-09 |
EP3929199A1 (en) | 2021-12-29 |
KR20200101219A (ko) | 2020-08-27 |
CA3130456C (en) | 2023-10-03 |
CA3130456A1 (en) | 2020-08-27 |
AU2020226042B2 (en) | 2022-07-14 |
BR112021016448A2 (pt) | 2021-11-09 |
CN113423710A (zh) | 2021-09-21 |
EP3929199A4 (en) | 2022-10-26 |
ZA202105970B (en) | 2023-05-31 |
EA202191991A1 (ru) | 2021-12-10 |
US20220135582A1 (en) | 2022-05-05 |
PE20211703A1 (es) | 2021-09-01 |
JP7358491B2 (ja) | 2023-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2021002165A1 (es) | Nuevos derivados de compuestos heterociclicos y uso de los mismos | |
UY38297A (es) | Compuestos derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona, composiciones, métodos y usos de los mismos | |
BR112021007788A8 (pt) | Composto inibidor de jak 2-azabiciclo hexano | |
PH12021551257A1 (en) | Cyclic pantetheine derivatives and uses thereof | |
MX2016016516A (es) | Inhibidores de fosfatidilinositol 3-cinasa. | |
MX2016016530A (es) | Inhibidores de fosfatidilinositol 3-quinasa. | |
CL2023000387A1 (es) | Derivados de dioxoloisoquinolinona novedosos y uso de los mismos | |
BR112021022536A2 (pt) | Derivado de fenilpropenilpiridina substituída e método de preparação do mesmo e uso médico do mesmo | |
CL2020001020A1 (es) | Derivados de bencimidazol y sus usos. | |
PE20240930A1 (es) | Analogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton | |
AR122351A1 (es) | Derivados de metilquinazolinona como inhibidores de braf | |
MX2019006843A (es) | Inhibidor de cdk4/6. | |
MX2020013694A (es) | Compuestos heterocíclicos como inhibidores de trk. | |
NI202100012A (es) | Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6 | |
UY37837A (es) | Nuevos compuestos heterocíclicos como inhibidores de cdk8/19 | |
EA202092829A1 (ru) | Композиции тофацитиниба с контролируемым высвобождением | |
CL2022003646A1 (es) | Derivados de amidopirimidona | |
BR112021011325A2 (pt) | Derivados de rapamicina | |
BR112020008258B8 (pt) | Compostos de biarila substituída ou seus sais farmaceuticamente aceitáveis, sua composição e seu uso como inibidores de indoleamina 2,3-dioxigenase (ido) | |
PH12020552186A1 (en) | Cyanotriazole compounds and uses thereof | |
CL2020002188A1 (es) | Compuestos de dihidropirimidinona o dihidrotriazinona fusionados con anillos saturados y su uso farmacéutico. | |
CO2020011860A2 (es) | Compuestos de 4–metildihidropirimidinona y su uso farmacéutico | |
DOP2019000299A (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
UY38006A (es) | Inhibidores de la quinasa mtor, composiciones farmacéuticas que los contienen, y al uso en terapia de tales compuestos y composiciones | |
DOP2020000088A (es) | Derivados de piridinona y su uso como inhibidores selectivos de alk2. |